Acción 1228 CANBRIDGE PHARMACEUTICALS INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas CANbridge Pharmaceuticals Inc.

Acciones

1228

KYG1821D1097

Mercado cerrado - Hong Kong S.E.
Otros sitios de cotización
 10:08:49 06/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,445 HKD -1,11 % Gráfico intradía de CANbridge Pharmaceuticals Inc. +7,23 % -55,05 %
22/04 CANbridge Pharmaceuticals Inc. anuncia los resultados del ensayo clínico de fase II CAN008 para el tratamiento del glioblastoma multiforme CI
28/03 CANbridge Pharmaceuticals Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CANbridge to Participate in Two Investor Conferences in September
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 1228
  4. Noticias CANbridge Pharmaceuticals Inc.
  5. Otros idiomas